ClinicalTrials.gg
CompletedNCT04420247Updated May 12, 2021

Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19

A Phase 3 interventional study of Chloroquine and Hydroxychloroquine in COVID, COVID-19 and SARS-CoV 2, sponsored by Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-12.

Sponsored by Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing chloroquine in COVID-19 — none open to participants now, none under way, none of them phase 3. Chloroquine · COVID-19.

Enrollment
8th of 15
142 · median 142
Started
2020
with 14 others
Phase 3
2 of 15
none open now
Registered
13th of 15
by date
Lead sponsor
1 of 15
Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva

Among the 15 studies testing chloroquine in COVID-19, this one is the 8th largest by enrollment, is one of 15 that started in 2020, is one of 2 in phase 3, and was the 13th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 15 studies testing chloroquine in COVID-19 is open now. The open studies under COVID-19, anywhere →

About chloroquine

Chloroquine: first FDA approval 1949 (ARALEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing chloroquine in COVID-19 as a file.
02

Study summary

Facing the challenge of finding an efficient treatment for COVID-19, the viral pneumonia caused by the Coronavirus SARS-Cov-2, this study intended to test if Chloroquine or Hydroxychloroquine, two drugs with strong in-vitro antiviral role proven by numerous studies and with a well defined safety profile established, for efficacy in treating COVID-19 and improving an ordinal primary outcome composed by a 9-levels scale, which was recomended by the World Health Organization.

Read the detailed description

This is a Phase 3, Pragmatic, Multicentric Randomized Controled Trial of efficacy to test the effect of either Chloroquine or Hydroxychloroquine for 5 days in the recomended dose standardized by brazilian Ministry of Health.

Patients were randomized (1:1) using stratified randomization by hospital and severity at the moment of randomization (stipulated by use of mechanical ventilation or not) into two arms: Intervention and Control. Intervention group recieved a loading dose of 900mg of Chloroquine or 800mg of Hydroxycloroquine in the first day, followed by 450mg of chloroquine of 400mg of hydroxychloroquine. Primary and secondary outcomes were evaluated on the 5th, 7th, 10th, 14th, 28th day after randomization.

Although the outcomes presented in the latest version were updated late on ClinicalTrials.org, on October 23, 2020, these outcomes were already present in the trial protocol approved by the Brazilian National Commission for Ethics in Research on April 8, 2020 (approval number: 3960331) and amending the protocol, approved by the same National Commission on May 25, 2020 (approval number: 4044848)

03

Conditions studied

  • COVID
  • COVID-19
  • SARS-CoV 2
  • Coronavirus
  • Corona Virus Infection

Keywords

  • VIRAL PNEUMONIA
  • CORONAVIRUS
  • COVID-19
  • COVID
  • SARS-COV-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult Males and non-pregnant females that accept and sign the .
  • Hospitalized with COVID-19 suspection that has collected the confirmatory test
  • To have at least one of thes symptoms: Fever, coughing, throat ache or runny nose.
  • To have at least one of these findings: radiological findings that indicates COVID-10 (bilatareal ground grass images); O2 saturation lower than 94% without supplementation and crackles in lung auscultation; Need of O2 supplementation; Need of Mechanical Ventilation.
  • Female patients must also agree to use efficient counterceptive methods during the evaluation period.

Exclusion criteria

Exclusion Criteria:

  • Patients with psoriasis or other exfoliative disease, porphyria, epilepsy, myasthenia gravis, advanced liver failure or glucose-6-phosphate dehydrogenase deficiency.
  • / AST> 5 times the .
  • Severe chronic kidney disease in stage 4 or requiring dialysis (ie, \<30).
  • Pregnancy or breastfeeding.
  • Early transfer to another hospital that is not a study site within 72 hours.
  • Severe heart disease and / or a history of cardiac arrhythmia.
  • Allergy to Chloroquine and / or Hydroxychloroquine.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Intervention

    Treatment with either Chloroquine or Hydroxychloroquine according to what was available in the hospital: Chloroquine - 900mg on the first day, followed by 450mg in the next 4 days. Hydroxychloroquine - 800mg on the first day, followed by 450mg in the next 4 days. + Standard treatment available and recomended by the Brazilian Guidelines for COVID-19.

    Drug: Chloroquine · Drug: Hydroxychloroquine

  • Active comparator
    Control

    Standard treatment available and recomended by the Brazilian Guidelines for COVID-19.

    Other: standard care

Interventions

  • 5 days of treatment with Chloroquine + Standard Care

  • 5 days of treatment with Hydroxychloroquine + Standard Care

  • Otherstandard care

    Standard Care according to Brazilian Guidelines for treating COVID-19

06

What researchers measure

Primary outcomes

  1. World Health Organization (WHO) 9-levels ordinal scale (from 0-8)

    Evaluation of the clinical status of patients on the 14th day after randomization defined by the 9-levels ordinal scale, with lower scores meaning better outcomes.

    Time frame: 14 days after randomization

Secondary outcomes

  1. World Health Organization (WHO) 9-levels ordinal scale (from 0-8)

    Evaluation of the clinical status of patients on the 5th, 7th, 10th and 28th day after randomization defined by the 9-levels ordinal scale, with lower scores meaning better outcomes.

    Time frame: 5, 7, 10 and 28 days after randomization

  2. Mortality

    All-cause mortality at 28 days after randomization

    Time frame: 28 days after randomization

  3. Ventilation free days

    Number of days without need of Mechanical Ventilation at 28 days after randomization

    Time frame: 28 days after randomization

  4. ICU Lenght of Stay

    ICU Lenght of Stay on survivors at 28 days after randomization

    Time frame: 28 days after randomization

  5. Hospital Lenght of Stay

    Hospital Lenght of Stay on survivors at 28 days after randomization

    Time frame: 28 days after randomization

  6. Acute Kidney Disease incidence

    Acute Kidney Disease incidence measured by Kidney Disease Improving Global Outcomes (KDIGO) stage 3 sometime until the 28th day after randomization.

    Time frame: 28 days after randomization

  7. Percentage of patients needing dialysis

    Percentage of patients needing dialysis sometime until the 28th day.

    Time frame: 28 days after randomization

  8. Coagulopathy incidence

    Presence of coagulopathy sometime until the 28th day (platelets \< 150000 and/or INR \>1.5 and/or KPTT \> 35 seconds).

    Time frame: 28 days after randomization

  9. Mean of C Reactive Protein Levels

    Mean of C Reactive Protein Levels on the 5th, 7th, 10th, 14th and 28th day after randomization, during period of hospitalization

    Time frame: 5, 7, 10, 14 and 28 days after randomization

  10. Sequential Organ Failure Assessment (SOFA) scores

    Sequential Organ Failure Assessment (SOFA) scores (range, 0-24, with higher scores indicating greater organ dysfunction) on the 5th, 7th, 10th, 14th and 28th day after randomization, during period of hospitalization.

    Time frame: 5, 7, 10, 14 and 28 days after randomization

  11. Neutrophils/lymphocytes ratio

    Neutrophils/lymphocytes ratio on the 5th, 7th, 10th, 14th and 28th day after randomization, during period of hospitalization.

    Time frame: 5, 7, 10, 14 and 28 days after randomization

Other outcomes

  1. Arrhythmia

    Safety outcome: Any kind of arrhythmia identified by the attending physician at the time of the intercurrence, confirmed by an electrocardiogram (ECG), sometime until the 28th day

    Time frame: 28 days after randomization

07

Study locations

1 site
  • Centro de Estudos e Pesquisa em Emergencias Clinicas e Terapia Intensiva
    Curitiba, Parana 82530200, Brazil
08

References and documents

Publications

  • Rea-Neto A, Bernardelli RS, Camara BMD, Reese FB, Queiroga MVO, Oliveira MC. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. Sci Rep. 2021 Apr 27;11(1):9023. doi: 10.1038/s41598-021-88509-9. PubMed 33907251 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Aug 2020, 4 months.

Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 4 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2020
First posted
Jun 9, 2020
StartActual
Apr 16, 2020
Primary completionActual
Aug 20, 2020
CompletionActual
Sep 3, 2020
Last update
May 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04420247
Lead sponsor
Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva
Responsible party
ALVARO REA-NETO, MD (Director of the Reseach Center, Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva) — Principal investigator
First posted
Jun 9, 2020
Start date
Apr 16, 2020
Primary completion
Aug 20, 2020
Completion
Sep 3, 2020
Last update
May 12, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Chloroquine · Hydroxychloroquine

Start the discussion